NCT05645744 - Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 29, 2021

Primary Completion Date

April 12, 2024

Study Completion Date

April 12, 2024

Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Chronic Lymphocytic Leukemia in RelapseSmall Lymphocytic Lymphoma, RelapsedWaldenstrom's Macroglobulinemia RecurrentFollicular B-cell Non-Hodgkin's LymphomaB-cell Lymphoma RefractoryMantle Cell Lymphoma RecurrentHairy Cell LeukemiaDiffuse Large B Cell LymphomaWaldenstrom's Macroglobulinemia RefractoryMantle Cell Lymphoma Refractory

Interventions

BIOLOGICAL

Prior MB-102 CAR-T cell investigational product.

No investigational product will be administered.

BIOLOGICAL

Prior MB-106 CAR-T cell investigational product.

No investigational product will be administered.

Trial Locations (5)

14642

University of Rochester Medical Center, Rochester

44195

Cleveland Clinic, Cleveland

98109

Fred Hutchinson Cancer Center, Seattle

92868-3201

UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange

02114

Massachusetts General Hospital, Boston